ABPI director general to step down

Dr Richard Barker will act as senior advisor to ABPI after handover to successor in May 2011

After more than six years at the helm of the Association of the British Pharmaceutical Industry (ABPI), Dr Richard Barker will step down as director general at the AGM in May 2011.

During his tenure, Barker has led the organisation through an evolution to establish the ABPI as an effective national association in its sector worldwide, building strong links with government and the health service and delivering initiatives to advance the reputation of the industry.

Barker said: ‘With the UK environment going through further rapid and dynamic evolution, next year will be a good time to hand over the reins to a new leader. I look forward to pursuing new opportunities outside the Association in the future, principally in healthcare. In the meantime, I am very much focused on continuing the vital work we are doing at the ABPI.’

The ABPI aims to appoint Barker’s successor next spring, which will allow the appointee to work with Simon Jose, current ABPI president, for a full year before the next change in president.

Following a handover to his successor in May 2011, Barker will act as a senior advisor to the ABPI for a period of up to 12 months.

You may also like

Media

Brexit White Paper - five key things for medicines

The ABPI, which represents innovative research-based biopharmaceutical companies in the UK, highlights five key points from the government's latest withdrawal plan
Media

Embracing new innovation in the face of Brexit

Dr Paul Catchpole commented at the NICE Annual Conference that adopting innovations will help bring investment into the UK and crucially help get more NHS patients onto ground breaking clinical trials programmes
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Media

New UK-wide agreement to speed up clinical trials and medicines research

Life Science leaders from across the UK have welcomed a new agreement that will make it easier for life-changing medicines and vaccines research and development to take place across different parts of the UK
Media

The pharma industry's response to PM’s latest Brexit speech

The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to the ‘Road to Brexit’ speech by Prime Minister Theresa May
Media

Life Science Industry Coalition position paper released

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
Media

Safeguarding public health must be number one priority

To coincide with the House of Commons Health Select Committee on <i>Brexit: the regulation of medicines, medical devices and substances of human origin</i>, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit
Subscribe now